Every minute, about four people around the world will be diagnosed with breast cancer, and it's estimated that 1 in 4 of them will develop metastatic disease, which remains incurable.

• While incredible progress has been made in the treatment of metastatic breast cancer (MBC), ongoing innovation, including advances in small molecule therapies, is essential to continue to drive meaningful improvements for patients.

Pfizer has deep expertise in breast cancer, having advanced new treatments that address different subtypes of the disease for over 25 years.

The background: In the 1970s and '80s, early research into how breast cancer cells divide and multiply laid the groundwork for the eventual discovery of a targeted small molecule approach to block cell division.

• Years of dedicated research and development in collaboration with academic researchers led to the FDA's initial approval of the first novel treatment for certain patients with MBC in over a decade.

The impact: Today, this small molecule is part of standard-of-care, first-line combination treatment and has been prescribed to over 900,000 patients in more than 100 countries. It continues to be selected as a combination partner in studies evaluating investigational MBC treatments in areas of high unmet need.

• Pfizer has supplemented its clinical trial research with real-world studies, including over 20,000 patients' experiences. These studies offer insights into how the treatment works in diverse patient groups, including men and those who are typically underrepresented in clinical trials.
• It has also provided crucial information to fill knowledge gaps on how medications work in real-world clinical practice.

Next steps: Despite available treatments, many people with certain types of MBC ultimately develop resistance to current therapies, which can lead to disease recurrence or progression.

Pfizer scientists are now exploring innovative treatment approaches through different combinations, modalities, and technologies to overcome this challenge.

• The company's pipeline leverages knowledge and key learnings based on decades of research in breast cancer, with a continued commitment to advancing new treatments, including small molecules, that can offer patients additional treatment options.

Each of these potential new treatments represents hope for people with MBC and their families, who are relying on biopharmaceutical companies like Pfizer to continue advancing scientific research to bring the next wave of breakthroughs that help people with cancer live better and longer lives.

To learn more about Pfizer's commitment to innovation in breast cancer, visit https://cancer.pfizer.com/breast-cancer.

The above content is sponsored by Pfizer Inc. and intended for U.S. residents only. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare professional. © 2025 Pfizer Inc. All rights reserved. PP-IBR-USA-7366 December 2025.